Clinical Trials Directory

Trials / Completed

CompletedNCT01503151

Cognitive Biases Modification Treatment for Social Anxiety

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
95 (actual)
Sponsor
Tel Aviv University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Adults with Social Phobia will be randomly assigned to either an attention bias modification treatment, interpretation bias modification treatment, both, or a placebo control condition not designed to change cognitive bias patterns. Outcome measures will be social anxiety symptoms and severity as measured by gold standard questionnaires as well as diagnosis of social phobia disorder and symptom counts derived from structured clinical interviews based on DSM-IV criteria. The investigators expect to find significant reduction in social anxiety symptoms in the Treatment groups relative to the placebo control group. The investigators want to find out the relative efficacy of attention and interpretation oriented treatments and the combination of the two.

Conditions

Interventions

TypeNameDescription
BEHAVIORALAttention Bias Modification Treatment (ABMT)Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
BEHAVIORALInterpretation Bias Modification (IBM)Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias.
BEHAVIORALControl ConditionAttention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns.
BEHAVIORALAttention and Interpretive biases modification (CBM)Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias.

Timeline

Start date
2012-01-01
Primary completion
2014-03-01
Completion
2014-03-01
First posted
2012-01-02
Last updated
2014-12-02

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT01503151. Inclusion in this directory is not an endorsement.